Eli Lilly reported $23.48B in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
AbbVie USD 13.82B 1.34B Jun/2026
Abbott USD 11.22B 655M Mar/2026
ALKERMES USD 459.09M 2.61M Sep/2026
Amgen USD 10.35B 126M Sep/2026
AstraZeneca USD 18.87B 11M Sep/2026
Baxter International USD 1.86B 158M Jun/2026
Biogen USD 2.38B 15.8M Sep/2026
Bristol-Myers Squibb USD 12.85B 976M Sep/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Drreddys Laboratories INR 101.4B 21.77B Sep/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.52B 451M Sep/2026
Glaxosmithkline GBP 11.31B 814.23M Sep/2026
J&J USD 19.05B 3.49B Jun/2026
Medtronic USD 6.36B 286M Jun/2026
Merck USD 12.56B 354M Jun/2026
Neurocrine Biosciences USD 957.3M 70.3M Sep/2026
Novartis USD 9.96B 109M Sep/2026
Novartis USD 9.96B 361M Sep/2026
Novo Nordisk DKK 114.94B 8.68B Jun/2026
Perrigo USD 685.5M 24.4M Sep/2026
Pfizer USD 17.57B 1.38B Sep/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 187.36M 4.56M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sanofi EUR 326M 166M Sep/2026
Sanofi EUR 492M 10M Jun/2026
United Therapeutics USD 348.6M 38.3M Sep/2026
Zoetis USD 1.69B 121M Sep/2026